Is Takeda (4502) Halal?
Shariah Screening — 5 Standards
Based on financial data from March 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 50.3% / 30% | 4.5% / 30% | 8.1% / 30% | 0.43% / 5% | ✗ NOT HALAL |
| DJIM | 50.3% / 33% | 4.5% / 33% | 8.1% / 33% | 0.43% / 5% | ✗ NOT HALAL |
| MSCI | 31.7% / 33% | 2.8% / 33% | 5.1% / 33% | 0.43% / 5% | ✓ HALAL |
| S&P | 50.3% / 33% | 4.5% / 33% | 8.1% / 33% | 0.43% / 5% | ✗ NOT HALAL |
| FTSE | 31.7% / 33% | 2.8% / 33% | 5.1% / 50% | 0.43% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 65.5% | |
| Operating Margin | 10.8% | |
| Net Margin | 2.5% | |
| Return on Equity (ROE) | 1.5% | |
| Return on Assets (ROA) | 2.5% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $1.1T |
| Free Cash Flow | $677.6B |
| Total Debt | $4.5T |
| Debt-to-Equity | 70.9 |
| Current Ratio | 1.2 |
| Total Assets | $14.2T |
Price & Trading
| Last Close | JPY 5,789.00 |
| 50-Day MA | JPY 5,529.58 |
| 200-Day MA | JPY 4,706.40 |
| Avg Volume | 5.1M |
| Beta | 0.1 |
|
52-Week Range
JPY 3,916.00
| |
About Takeda (4502)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Takeda (4502) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Takeda is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Takeda's debt ratio?
Takeda's debt ratio is 50.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 31.7%.
What are Takeda's key financial metrics?
Takeda has a market capitalization of $9.2T, trailing P/E ratio of 82.6, and revenue of $4.6T. The company maintains a gross margin of 65.5% and a net margin of 2.5%. Return on equity stands at 1.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.